Skip to main content
Clinical Trials/NCT03985605
NCT03985605
Completed
Not Applicable

Therapeutic Drug Monitoring of Antiinfectives for Patients With Severe Illness

Ludwig-Maximilians - University of Munich1 site in 1 country500 target enrollmentJanuary 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infection, Bacterial
Sponsor
Ludwig-Maximilians - University of Munich
Enrollment
500
Locations
1
Primary Endpoint
Correlation of meropenem concentration in serum to the concentration in brain fluid
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Therapeutic drug monitoring of antiinfectives in intensive care patients is an usual research topic of the last years. Based on research result, which have shown subtherapeutic plasma concentrations of antibiotics, a routines therapeutic drug monitoring for β-lactam-antibiotics was implemented in January 2018 at Clinic for Anesthesiology at University Hospital, LMU Munich, Germany. This study is an prospective evaluation of these TDM-program.

Detailed Description

Bacterial infections are associated with high mortality in intensive care patients. Antibiotic therapy is the only causal opportunity to treat those infections. Pharmacokinetic and -dynamic changes in critically ill patients lead to unpredictable plasma concentrations of the applied drugs. Research results of the last years with many quantified plasma concentrations in subtherapeutic levels yield to the recommendation of the Paul-Ehrlich-Society for an routines therapeutic drug monitoring of antibiotics in intensive care patients. These was implemented in January 2018 at Clinic for Anesthesiology at University Hospital, LMU Munich, Germany for all intensive care patients as a routines procedure. The introduced study is a prospective evaluation of the TDM-program with regard to improvement opportunity, influencing factors and parallels to other studies.

Registry
clinicaltrials.gov
Start Date
January 1, 2018
End Date
January 1, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michael Zoller MD

Principal Investigator

Ludwig-Maximilians - University of Munich

Eligibility Criteria

Inclusion Criteria

  • routines TDM of antiinfectives

Exclusion Criteria

  • TDM is not available

Outcomes

Primary Outcomes

Correlation of meropenem concentration in serum to the concentration in brain fluid

Time Frame: during the treatment with an external ventricular drainage

The concentration of meropenem in the brain fluid of 30 patients with an external ventricular drainage will be correlated to their serum concentration

Incidence of subtherapeutic antiinfective concentrations

Time Frame: four years

Number of subtherapeutic concentrations from different antiinfectives in critically ill patients

Subtherapeutic antiinfective concentrations during hemoadsorption

Time Frame: during hemoadsorption treatment

Subtherapeutic concentrations of antiinfectives in serum during hemoadsorption treatment

Secondary Outcomes

  • 28-day mortality of patients with therapeutic drug monitoring of antiinfectives(during intensive care treatment)
  • ICU-free days of patients with therapeutic drug monitoring of antiinfectives(during intensive care treatment)
  • Sofa-score course of patients with therapeutic drug monitoring of antiinfectives(during the treatment with the antiinfectives)
  • Time course of Interleukin-6 in patients with therapeutic drug monitoring of antiinfectives(during the treatment with the antiinfectives)
  • Time course of CRP in patients with therapeutic drug monitoring of antiinfectives(during the treatment with the antiinfectives)

Study Sites (1)

Loading locations...

Similar Trials